Nimbus Therapeutics’ midphase psoriasis data have persuaded Takeda that the biotech’s TYK2 inhibitor will be big. How big? $4 billion upfront and more again on the back end. Late last month, Nimbus ...
Mid-tropospheric circulation features under essentially clear sky conditions have been noted in the data of the 6.7 μm channel of the Nimbus 4 Temperature-Humidity Infrared Radiometer (THIR) while at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results